Vanguard Group’s Collegium Pharmaceutical COLL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $104M | Buy |
2,256,254
+29,876
| +1% | +$1.25M | ﹤0.01% | 1857 |
|
|
2025
Q3 | $77.9M | Sell |
2,226,378
-21,833
| -1% | -$759K | ﹤0.01% | 1963 |
|
|
2025
Q2 | $66.5M | Buy |
2,248,211
+1,643
| +0.1% | +$46.9K | ﹤0.01% | 2004 |
|
|
2025
Q1 | $67.1M | Sell |
2,246,568
-36,098
| -2% | -$1.1M | ﹤0.01% | 1964 |
|
|
2024
Q4 | $65.4M | Sell |
2,282,666
-63,876
| -3% | -$2.11M | ﹤0.01% | 2046 |
|
|
2024
Q3 | $90.7M | Sell |
2,346,542
-24,400
| -1% | -$870K | ﹤0.01% | 1918 |
|
|
2024
Q2 | $76.3M | Buy |
2,370,942
+40,214
| +2% | +$1.39M | ﹤0.01% | 1963 |
|
|
2024
Q1 | $90.5M | Buy |
2,330,728
+17,942
| +0.8% | +$628K | ﹤0.01% | 1915 |
|
|
2023
Q4 | $71.2M | Sell |
2,312,786
-26,310
| -1% | -$659K | ﹤0.01% | 2032 |
|
|
2023
Q3 | $52.3M | Buy |
2,339,096
+2,339
| +0.1% | +$53.3K | ﹤0.01% | 2118 |
|
|
2023
Q2 | $50.2M | Buy |
2,336,757
+30,817
| +1% | +$700K | ﹤0.01% | 2184 |
|
|
2023
Q1 | $55.3M | Buy |
2,305,940
+97,829
| +4% | +$2.59M | ﹤0.01% | 2129 |
|
|
2022
Q4 | $51.2M | Sell |
2,208,111
-92,076
| -4% | -$1.86M | ﹤0.01% | 2176 |
|
|
2022
Q3 | $36.8M | Buy |
2,300,187
+25,801
| +1% | +$455K | ﹤0.01% | 2327 |
|
|
2022
Q2 | $40.3M | Sell |
2,274,386
-32,143
| -1% | -$541K | ﹤0.01% | 2295 |
|
|
2022
Q1 | $47M | Buy |
2,306,529
+19,112
| +0.8% | +$361K | ﹤0.01% | 2338 |
|
|
2021
Q4 | $42.7M | Sell |
2,287,417
-57,065
| -2% | -$1.11M | ﹤0.01% | 2443 |
|
|
2021
Q3 | $46.3M | Buy |
2,344,482
+104,093
| +5% | +$2.25M | ﹤0.01% | 2408 |
|
|
2021
Q2 | $53M | Buy |
2,240,389
+54,009
| +2% | +$1.25M | ﹤0.01% | 2341 |
|
|
2021
Q1 | $51.8M | Buy |
2,186,380
+455,528
| +26% | +$10.8M | ﹤0.01% | 2296 |
|
|
2020
Q4 | $34.7M | Buy |
1,730,852
+58,222
| +3% | +$1.14M | ﹤0.01% | 2381 |
|
|
2020
Q3 | $34.8M | Sell |
1,672,630
-25,603
| -2% | -$462K | ﹤0.01% | 2200 |
|
|
2020
Q2 | $29.7M | Sell |
1,698,233
-1,427
| -0.1% | -$27.9K | ﹤0.01% | 2242 |
|
|
2020
Q1 | $27.8M | Buy |
1,699,660
+19,006
| +1% | +$392K | ﹤0.01% | 2140 |
|
|
2019
Q4 | $34.6M | Buy |
1,680,654
+116,944
| +7% | +$1.95M | ﹤0.01% | 2281 |
|
|
2019
Q3 | $18M | Sell |
1,563,710
-7,764
| -0.5% | -$88.6K | ﹤0.01% | 2539 |
|
|
2019
Q2 | $20.7M | Buy |
1,571,474
+22,883
| +1% | +$306K | ﹤0.01% | 2498 |
|
|
2019
Q1 | $23.4M | Buy |
1,548,591
+124,844
| +9% | +$2M | ﹤0.01% | 2429 |
|
|
2018
Q4 | $24.4M | Buy |
1,423,747
+48,038
| +3% | +$822K | ﹤0.01% | 2359 |
|
|
2018
Q3 | $20.3M | Buy |
1,375,709
+113,038
| +9% | +$2M | ﹤0.01% | 2571 |
|
|
2018
Q2 | $30.1M | Buy |
1,262,671
+152,508
| +14% | +$3.75M | ﹤0.01% | 2379 |
|
|
2018
Q1 | $28.4M | Buy |
1,110,163
+65,655
| +6% | +$1.56M | ﹤0.01% | 2356 |
|
|
2017
Q4 | $19.3M | Buy |
1,044,508
+136,562
| +15% | +$1.96M | ﹤0.01% | 2501 |
|
|
2017
Q3 | $9.53M | Buy |
907,946
+119,689
| +15% | +$1.32M | ﹤0.01% | 2833 |
|
|
2017
Q2 | $9.86M | Sell |
788,257
-18,282
| -2% | -$181K | ﹤0.01% | 2779 |
|
|
2017
Q1 | $8.11M | Buy |
806,539
+58,398
| +8% | +$868K | ﹤0.01% | 2849 |
|
|
2016
Q4 | $11.6M | Buy |
748,141
+225,553
| +43% | +$3.75M | ﹤0.01% | 2678 |
|
|
2016
Q3 | $10.1M | Buy |
522,588
+36,779
| +8% | +$437K | ﹤0.01% | 2681 |
|
|
2016
Q2 | $5.76M | Buy |
485,809
+36,987
| +8% | +$611K | ﹤0.01% | 2910 |
|
|
2016
Q1 | $8.15M | Buy |
448,822
+200,501
| +81% | +$3.64M | ﹤0.01% | 2721 |
|
|
2015
Q4 | $6.83M | Buy |
248,321
+61,429
| +33% | +$1.29M | ﹤0.01% | 2835 |
|
|
2015
Q3 | $4.13M | Buy |
186,892
+105,274
| +129% | +$1.9M | ﹤0.01% | 3059 |
|
|
2015
Q2 | $1.46M | Buy |
+81,618
| New | +$1.41M | ﹤0.01% | 3547 |
|
Other funds holding COLL
EAM
RCMNY
Vanguard Group's COLL Position: Q4 2025 in Review
Vanguard Group increased its Collegium Pharmaceutical (COLL) stake by 1.3% in Q4 2025, buying an estimated $1.25M and bringing the position to 2,256,254 shares worth $104M. The position accounts for ﹤0.01% of the portfolio, ranked #1857.
Vanguard Group first reported a position in COLL in Q2 2015 and has held it in 43 quarters since. 278 funds tracked by Wall St. Rank hold COLL as of Q4 2025.
- Vanguard Group held 2,256,254 shares of Collegium Pharmaceutical worth $104M as of Q4 2025.
- Vanguard Group bought 29,876 Collegium Pharmaceutical shares in Q4 2025, an estimated $1.25M.
- Collegium Pharmaceutical made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1857 holding.
- Vanguard Group first reported a position in Collegium Pharmaceutical in Q2 2015 and has held it in 43 quarters since.
- 278 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.